Expression of BAG-1 in Invasive Breast Carcinomas
- 1 June 1999
- journal article
- breast cancer
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 17 (6) , 1710
- https://doi.org/10.1200/jco.1999.17.6.1710
Abstract
PURPOSE: The purpose of this study was to retrospectively evaluate the expression of BAG-1 in invasive breast carcinomas. The intensity and subcellular distribution of BAG-1 expression was correlated with conventional prognostic factors and with disease-free and overall survival. PATIENTS AND METHODS: One hundred forty patients diagnosed with invasive breast cancer in St. John's, Newfoundland, between 1986 and 1996 were included in the study. The median follow-up of the study was 8 years. Expression of BAG-1 was determined by immunohistochemical staining of paraffin-embedded breast tumor tissues. RESULTS: Of the 140 breast carcinomas examined, 77.1% were positive for BAG-1 expression. Except for differentiation, no correlation was observed between BAG-1 expression and conventional prognostic factors such as age, histology, stage, and estrogen and progesterone receptor status. In multivariate analysis, BAG-1 expression was significantly associated with shorter disease-free (P = .0052) and overall survival (P = .0033). Patients whose tumors expressed nuclear BAG-1 tended to have a shorter disease-free (63 v 84 months; P = 0.4493) and overall (69 v 99 months, P = .1009) survival. CONCLUSION: BAG-1 is overexpressed in the majority of invasive breast carcinomas. Although BAG-1 did not correlate with conventional prognostic factors, its overexpression, especially the nuclear expression, may be associated with a shorter disease-free and overall survival. Our preliminary data strongly indicate that further investigation is warranted to define the role of BAG-1 as an independent prognostic factor in patients with newly diagnosed breast cancer.Keywords
This publication has 34 references indexed in Scilit:
- Is p53 a protein that predicts the response to chemotherapy in node negative breast cancer?Breast Cancer Research and Treatment, 1998
- Expression of Bcl-2 in human breast cancer: Correlation between hormone receptor status, p53 protein accumulation and DNA strand breaks associated with apoptosisPathology International, 1997
- Clinical significance of bcl-2 gene expression in human breast cancer tissuesBreast Cancer Research and Treatment, 1997
- Bcl-2 and p53 expression in node-negative breast carcinoma: A study with long-term follow-upHuman Pathology, 1996
- p53 and P-glycoprotein are often co-expressed and are associated with poor prognosis in breast cancerBritish Journal of Cancer, 1996
- Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patientsNature Medicine, 1996
- Apoptosis suppressing protein bcl‐2 is expressed in well‐differentiated breast carcinomas with favourable prognosisThe Journal of Pathology, 1995
- Multiple expression patterns of biopathological markers in primary invasive breast carcinoma: A useful tool for elucidating its biological behaviourAnnals of Oncology, 1995
- Expression of BCL-2 in primary breast cancer and its correlation with tumour phenotypeAnnals of Oncology, 1994
- Clinical significance of bcl-2-MBR gene rearrangement and protein expression in diffuse large-cell non-Hodgkin's lymphoma: an analysis of 83 cases.Journal of Clinical Oncology, 1994